Rachel L Navarra, PhD
Affiliations: | 2010-2016 | Pharmacology and physiology | Drexel University College of Medicine, Philadelphia, PA, United States |
| 2016- | Cell biology and neuroscience | Rowan University School of Osteopathic Medicine |
Google:
"Rachel Navarra"Mean distance: (not calculated yet)
Parents
Sign in to add mentor
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Knapp CP, Papadopoulos E, Loweth JA, et al. (2024) Perturbations in Risk/Reward Decision Making and Frontal Cortical Catecholamine Regulation Induced by Mild Traumatic Brain Injury. Behavioural Brain Research. 115002 |
| Waterhouse BD, Navarra RL. (2018) The locus coeruleus-norepinephrine system and sensory signal processing: A historical review and current perspectives. Brain Research |
| Navarra RL, Waterhouse BD. (2018) Considering noradrenergically mediated facilitation of sensory signal processing as a component of psychostimulant-induced performance enhancement. Brain Research |
| Navarra R, Waterhouse B. (2018) "What have we GANEd?" A theoretical construct to explain experimental evidence for noradrenergic regulation of sensory signal processing. The Behavioral and Brain Sciences. 39: e219 |
| Navarra RL, Clark BD, Gargiulo AT, et al. (2016) Methylphenidate Enhances Early Stage Sensory Processing and Rodent Performance of a Visual Signal Detection Task. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology |
| Navarra RL, Clark BD, Zitnik GA, et al. (2013) Methylphenidate and atomoxetine enhance sensory-evoked neuronal activity in the visual thalamus of male rats. Experimental and Clinical Psychopharmacology. 21: 363-74 |
| Brennan JA, Graf R, Grauer SM, et al. (2010) WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. The Journal of Pharmacology and Experimental Therapeutics. 332: 190-201 |
| Grauer SM, Pulito VL, Navarra RL, et al. (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. The Journal of Pharmacology and Experimental Therapeutics. 331: 574-90 |
| Grauer SM, Graf R, Navarra R, et al. (2009) WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics. Psychopharmacology. 204: 37-48 |
| Liu F, Grauer S, Kelley C, et al. (2008) ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. The Journal of Pharmacology and Experimental Therapeutics. 327: 827-39 |